JP2009525046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525046A5 JP2009525046A5 JP2008553336A JP2008553336A JP2009525046A5 JP 2009525046 A5 JP2009525046 A5 JP 2009525046A5 JP 2008553336 A JP2008553336 A JP 2008553336A JP 2008553336 A JP2008553336 A JP 2008553336A JP 2009525046 A5 JP2009525046 A5 JP 2009525046A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- kinase
- synuclein
- activity
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76400006P | 2006-01-31 | 2006-01-31 | |
| PCT/US2007/002685 WO2007089862A2 (en) | 2006-01-31 | 2007-01-30 | Alpha-synuclein kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525046A JP2009525046A (ja) | 2009-07-09 |
| JP2009525046A5 true JP2009525046A5 (https=) | 2010-04-08 |
Family
ID=38328036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553336A Pending JP2009525046A (ja) | 2006-01-31 | 2007-01-30 | アルファ−シヌクレインキナーゼ |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7553639B2 (https=) |
| EP (1) | EP1989330A4 (https=) |
| JP (1) | JP2009525046A (https=) |
| CA (1) | CA2641219A1 (https=) |
| WO (1) | WO2007089862A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1989330A4 (en) | 2006-01-31 | 2009-10-21 | Elan Pharm Inc | ALPHA-SYNUCLEINE KINASE |
| JP2011515072A (ja) * | 2008-02-13 | 2011-05-19 | エラン ファーマ インターナショナル リミテッド | α−シヌクレインキナーゼ |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| EP2408772B1 (en) * | 2009-03-19 | 2015-07-01 | Medical Research Council Technology | Compounds |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| EP2426202A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Kinases as targets for anti-diabetic therapy |
| US9458463B2 (en) | 2010-09-03 | 2016-10-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for treatment of diabetes by a small molecule inhibitor for GRK5 |
| EP2962115A1 (en) * | 2013-02-26 | 2016-01-06 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Method for the assay of synucleins |
| WO2018057782A1 (en) * | 2016-09-23 | 2018-03-29 | University Of Utah Research Foundation | Methods of preventing stem cell differentiation using a pask inhibitor |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| US20210041461A1 (en) | 2018-03-14 | 2021-02-11 | Yissum Research Developmen Company Of The Hebrew University Of Jerusalem Ltd | Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies |
| DK4172199T3 (da) | 2020-06-26 | 2025-08-18 | Bioarctic Ab | Alfa-synuklein-protofibril-bindende antistoffer |
| CN114601928B (zh) * | 2022-04-02 | 2023-03-17 | 首都医科大学 | 一种钙超载介导神经元死亡的标志物及应用 |
| CN115569202A (zh) * | 2022-10-19 | 2023-01-06 | 苏州捷乐思生物科技有限公司 | 一种帕金森综合征动物模型、药物筛选方法及治疗药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276643B2 (en) | 2000-02-18 | 2007-10-02 | The Regents Of The University Of California | Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents |
| WO2002004482A1 (en) * | 2000-07-07 | 2002-01-17 | Panacea Pharmaceuticals, Inc. | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| US20060079503A1 (en) | 2002-05-03 | 2006-04-13 | Schering Aktiengesellschaft | Thiazolidinones and the use therof as polo-like kinase inhibitors |
| WO2004069175A2 (en) * | 2003-02-02 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE10351744A1 (de) | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7566548B2 (en) | 2004-08-13 | 2009-07-28 | University Of Massachusetts | Methods for identifying therapeutic agents and for treating disease |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| JP4939432B2 (ja) | 2004-12-01 | 2012-05-23 | ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ | α−シヌクレイン毒性のモジュレーター |
| BRPI0519040A2 (pt) * | 2004-12-15 | 2009-01-13 | Bayer Schering Pharma Ag | tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| DE102005020104A1 (de) | 2005-04-25 | 2006-10-26 | Schering Ag | Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel |
| US20070010565A1 (en) | 2005-04-25 | 2007-01-11 | Olaf Prien | New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |
| US9018003B2 (en) * | 2005-05-13 | 2015-04-28 | Whitehead Institute For Biomedical Research | Modulators of alpha-synuclein toxicity |
| WO2007059219A1 (en) | 2005-11-15 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| JP5237108B2 (ja) | 2005-12-08 | 2013-07-17 | アボット・ラボラトリーズ | タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物 |
| ES2545907T3 (es) | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| EP1989330A4 (en) | 2006-01-31 | 2009-10-21 | Elan Pharm Inc | ALPHA-SYNUCLEINE KINASE |
| JP2011515072A (ja) | 2008-02-13 | 2011-05-19 | エラン ファーマ インターナショナル リミテッド | α−シヌクレインキナーゼ |
-
2007
- 2007-01-30 EP EP07762749A patent/EP1989330A4/en not_active Withdrawn
- 2007-01-30 US US11/669,093 patent/US7553639B2/en not_active Expired - Fee Related
- 2007-01-30 WO PCT/US2007/002685 patent/WO2007089862A2/en not_active Ceased
- 2007-01-30 JP JP2008553336A patent/JP2009525046A/ja active Pending
- 2007-01-30 CA CA002641219A patent/CA2641219A1/en not_active Abandoned
-
2008
- 2008-02-13 US US12/030,849 patent/US20080300206A1/en not_active Abandoned
-
2010
- 2010-02-08 US US12/702,201 patent/US8148089B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525046A5 (https=) | ||
| Seifert et al. | The influence of fundamental traits on mechanisms controlling appendage regeneration | |
| Bahi et al. | Dopamine transporter (DAT) knockdown in the nucleus accumbens improves anxiety-and depression-related behaviors in adult mice | |
| Fiorentini et al. | Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice | |
| Von Koch et al. | Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice | |
| Hasegawa et al. | Distinct and Cooperative Functions for the Protocadherin-α,-β and-γ Clusters in Neuronal Survival and Axon Targeting | |
| Gioia et al. | The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta | |
| Koprich et al. | Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease | |
| Sennvik et al. | Tau‐4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice | |
| JP2003517580A5 (https=) | ||
| WO2017172733A1 (en) | Anti-ryk antibodies and methods of using the same | |
| CN114286710A (zh) | 治疗亨廷顿病的方法和材料 | |
| CN110628814B (zh) | 基于基因编辑技术增加smn蛋白表达的方法及其在sma治疗中的应用 | |
| Rahman et al. | Early postnatal lead exposure induces tau phosphorylation in the brain of young rats | |
| Backman et al. | Targeted disruption of mouse Dach1 results in postnatal lethality | |
| CN101942463B (zh) | 一种建立急性多型性卟啉病转基因小鼠模型的方法 | |
| EP1221283A3 (en) | Transgenic animal for screening therapeutic agents for brain tumors | |
| CN108719145B (zh) | 一种用于筛选治疗帕金森病药物的斑马鱼模型构建方法 | |
| CN118421703B (zh) | 一种自发出现情绪异常波动的非人哺乳动物模型的构建方法及其用途 | |
| WO2006026478A3 (en) | Compositions and methods for improving heart function | |
| KR100734815B1 (ko) | Ｈｔａｕ24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법 | |
| Götz et al. | Human tau transgenic mice: towards an animal model for neuro-and glialfibrillary lesion formation | |
| KR100635865B1 (ko) | Ａｐｐ/ｃ-105 돌연변이 유전자를 발현하는 형질전환 치매마우스 | |
| US20060134659A1 (en) | Method for demethylating target methylated region of genome DNA | |
| Patil | Effects of Ablation of Fibroblasts on the Structure and Function of Salivary Gland |